Ultimovacs - New large indication for UV1
Ultimovacs has made the decision to expand its R&D pipeline with a new indication, non-small cell lung cancer (NSCLC), for its lead asset the therapeutic cancer vaccine, UV1. The sponsorship arrangement will be similar to most of the other Phase II trials: Ultimovacs will work closely with the lead investigator and will provide financial support. The company will be able to continue the development if the Phase II data are positive. Despite significant progress being made with the advent of immunotherapies, NSCLC is still a challenging cancer to manage. Ultimovacs aims to position UV1 as a combination therapy with Keytruda in a first-line setting, which means it is targeting the biggest share of the large NSCLC market. We adjust our model to include the new opportunity and increase our valuation to NOK6.13bn or NOK179/sh (from NOK128/sh).Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.